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Abstract
Next to outer hair cell dysfunction, age-related hearing loss may be explained by apolipoprotein E (APOE) genotype. In the Leiden
85-plus Study, a population-based study, the participants were 85 years old. We measured hearing loss by pure-tone audiometry in 435
participants in relation to APOE. Results demonstrated that those with the APOE-4/4 genotype had the highest levels of hearing loss (n 
6; 56.1 dB), those with the APOE-3/4 or 2/4 genotype (n  89) had intermediate levels of hearing loss (51.0 dB), and those without
the APOE-4 allele (n  340) had the lowest levels of hearing loss (48.9 dB), p for trend  0.02. Eighty percent of participants had hearing
loss of 35 dB and more, that is, hearing impairment. The APOE-4 allele was associated with a 2.0-fold increased risk of hearing impairment
(confidence interval [CI 95%], 1.0–4.0), compared with those without the APOE-4 allele. The risk for hearing impairment in subjects with
the APOE-4 allele remained similar after adjustment for cardiovascular disease, stroke, and cognitive impairment. Our results suggest that
the APOE-4 allele contributes to age-related hearing loss.
© 2012 Elsevier Inc. All rights reserved.
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The prevalence and severity of hearing loss increases
with age (Gates and Mills, 2005). Age-related hearing loss
affects up to 80% of people aged 80 years and more. It is a
disabling condition associated with problems in daily life,
social isolation, depression, and a lower quality of life
(Gates and Mills, 2005). Because of the impact of age-
related hearing loss on all aspects of everyday life and
possibilities for prevention, it is essential to understand
more about the pathophysiological basis of this disorder.
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http://dx.doi.org/10.1016/j.neurobiolaging.2012.04.001Population-based studies, neuropathological studies, and
animal studies suggest that generalized atherosclerosis con-
tributes to age-related hearing loss (Gates and Mills, 2005;
Cruickshanks et al., 1998; Helzner et al., 2011; Gratton et
al., 1996; Spicer and Schulte, 2002). Neurophysiological
studies show that there is a reduction of amplitudes of action
potentials recorded in animal models, indicating diminished
neural activity in the auditory nerve (Spiess et al., 2002;
Schulte and Schmiedt, 1992). The basis of this diminished
activity can possibly be attributed to primary degeneration
of spiral ganglion cells, that is, the group of nerve cells that
send a representation of sound from the cochlea to the brain
(Spiess et al., 2002; Schulte and Schmiedt, 1992).
The apolipoprotein E (APOE) genotype is unique. Stud-
ies show that APOE contributes to maintenance and repair
of neuronal cell membranes; moreover, it is the strongest
genetic risk factor, contributing to age-related disorders
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degeneration (McKay et al., 2011). We hypothesized that
the APOE genotype contributes to age-related hearing loss;
we are unaware of other studies assessing the contribution
of APOE genotype to age-related hearing loss. We deter-
mined whether APOE contributes to age-related hearing
loss in an unselected population-based cohort of elderly
individuals aged 85 years.
2. Methods
2.1. The Leiden 85-plus Study
The Leiden 85-plus Study is a population-based study of
inhabitants of the city of Leiden. Between 1 September
1997 and 1 September 1999, 599 participants aged 85 years
were enrolled (response 87%) (Gussekloo et al., 2003). The
Medical Ethical Committee of the Leiden University Med-
ical Center approved the study, and all participants gave
informed consent.
2.2. Hearing
Within the first year of the baseline measurement, all
participants of the Leiden 85-plus Study were invited to
participate in the additional hearing study. During a home
visit by a physician or a trained assistant, audiological tests
were performed and questionnaires on hearing loss were
administered (Gussekloo et al., 2003). Excessive cerumen,
if present, was removed from the participant’s ears before
audiometric measurements. Hearing loss was measured us-
ing pure-tone audiometry because pure-tone audiometry is
the golden standard to determine hearing threshold (Gates
and Mills, 2005; Cruickshanks et al., 1998; Helzner et al.,
2011). We therefore used a portable Diagnostic Audiometer
(AD 28 Interacoustics, Assens, Denmark). Air conduction
hresholds were obtained separately for the left and right ear
t frequencies of 250, 500, 1000, 2000, 4000, and 8000 Hz.
hen necessary, masking was added to the opposite ear.
pecial attention was paid to reducing possible effects of
ackground noise. Hearing loss was estimated as the aver-
ge hearing loss in dB at 1000, 2000, and 4000 Hz for the
est ear (Fletcher index). Hearing impairment was defined
s a hearing loss more than 35 dB for the best ear, in line
ith the Dutch health authorities’ definition.
.3. APOE genotype
Two common nucleotide polymorphisms constitute the
2/3/4 alleles. For genotyping, two TaqMan assays were
sed (Applied Biosystems, Foster City, CA, USA).
.4. Possible confounders
Generalized atherosclerosis and cognitive impairment
ere considered possible confounders because these are
ge-related disorders associated with APOE genotype. Mea-
urements of generalized atherosclerosis had special empha-
is within the Leiden 85-plus Study (Gussekloo et al., 2003).
he burden of generalized atherosclerosis was rated by the Aresence of cardiovascular pathology at baseline, as as-
essed by history taking from treating physicians and elec-
rocardiography (ECG). Cardiovascular pathologies in-
luded 1) myocardial infarction (clinical diagnosis or on
CG), 2) angina pectoris or myocardial ischemia on ECG,
) claudicatio intermittens, and 4) arterial surgery. For all
articipants, ECGs were recorded on a Siemens Siccard 440
Erlangen, Germany) and transmitted electronically to the
CG Core Laboratory in Glasgow for automated Minnesota
oding. Myocardial infarction was assessed by Minnesota
odes 1-1, 1-2, and 1-3, and myocardial ischemia was as-
essed by Minnesota codes 4-1, 4-2, 4-3, 5-1, 5-2, and 5-3.
his approximation for the burden of generalized athero-
clerosis follows the classification from the Second Mani-
estation of ARTerial Disease Study, an established proxy
or generalized atherosclerosis, which showed that the num-
er of cardiovascular pathologies is related to the severity of
therosclerosis measured as intima-media thickness and ar-
erial stiffness (Simons et al., 1999). Cognitive impairment
as defined as a Mini-Mental State Examination score
ower than 24 points (Tombaugh and McIntyre, 1992). The
resence of stroke in medical history was assessed by in-
erviewing treating physicians of all participants. Stroke
as considered a possible confounder because it could be
rgued that stroke can involve hearing loss owing to damage
ithin the central auditory pathways, whereas we intended
o determine hearing loss associated with age-related hear-
ng loss, that is, peripheral auditory pathways; moreover,
ncidence and outcome of stroke could be associated with
POE genotype (Martínez-González and Sudlow, 2006;
iffi et al., 2010).
.5. Statistical analysis
We examined the association between APOE genotype
nd risk of hearing impairment, using standard logistic
egression models. The various APOE alleles were catego-
ized into two categories, that is, presence or absence of the
POE-4 allele. Risks for hearing impairment were esti-
ated with odds ratios using those without the APOE-4
llele as reference. In an additional analysis, we adjusted for
ossible confounders, including generalized atherosclerosis,
troke, and cognitive impairment. Furthermore, we deter-
ined the strength of association using linear mixed mod-
ls, that is, we determined the p for trend for APOE geno-
ype (those without the APOE-4 allele vs. those with one
POE-4 allele vs. homozygote APOE-4/4 participants)
gainst hearing loss as measured at baseline. These models
se all available data and appropriately handle missing data.
wing to their flexibility, mixed models are the preferred
hoice for the analysis of such data. The models we used
lso included APOE genotypes and hearing loss at 250, 500,
000, 2000, 4000, and 8000 Hz. The estimate for the vari-
us APOE genotypes reflects the impact of the different
POE alleles (those without the APOE-4 allele vs. those
hart of
A
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ticipants) on hearing loss.
3. Results
3.1. Participants
Data on hearing in 454 participants in the hearing study
from the Leiden 85-plus Study have been described else-
Fig. 1. Flowc
Table 1






Low level of education 386 (64
Cardiovascular disease 378 (63
Stroke 62 (10
Cognition (median MMSE score) 27
Hearing loss
Overall hearing loss (dB, mean, sd)a —
Hearing impairmentb —







Total 4-carrier (either 24, 34, 44) 128 (23
a Hearing loss was estimated as the average hearing loss in dB at 1000
b Hearing impairment is defined as a hearing loss of more than 35 dB,
c APOE genotype was determined in the total cohort of participants (participants included in the current study (n  435); number of subjects andwhere (Gussekloo et al., 2003). Complete hearing data and
APOE genotype were available for 435 participants (Fig. 1).
The baseline characteristics of the total cohort, that is, all
participants from the Leiden 85-plus Study, and the 435
participants with complete data on hearing loss and APOE
genotype are given in Table 1. There were no significant
differences in sociodemographic and clinical characteristics
between the 435 participants from the current study and the
participants.







107 (65.2%) 290 (66.7%)
111 (67.7%) 275 (63.2%)
101 (61.6%) 279 (64.1%)
24 (14.6%) 38 (8.7%)
— 49.4 (14.7)
— 358 (82.3%)
(n  113) (n  435)
3 (2.7%) 1 (0.2%)
23 (20.3%) 69 (15.9%)
2 (1.8%) 11 (2.5%)
55 (48.7%) 270 (62.1%)
23 (20.3%) 78 (17.9%)
7 (6.2%) 6 (1.4%)
32 (28.3%) 95 (21.8%)
and 4000 Hz with the best ear.
ed with the best ear, at 1000, 2000, and 4000 Hz.
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not participating in the hearing study (chi-square, all p 
.05).
.2. APOE and hearing
Figure 2 shows that those with the APOE-4/4 geno-
ype had the highest levels of hearing loss (n  6; overall
ean hearing loss, 56.1 dB), those with the APOE-3/4 or
2/4 genotype (n  89) had intermediate levels of hearing
oss (51.0 dB), and those without the APOE-4 allele (n 
40) had the lowest levels of hearing loss (48.9 dB), p for
rend  0.02. Presence of cardiovascular disease was asso-
ciated with a 2.4-fold increased risk of hearing impairment
compared with those without cardiovascular disease (Table
2). No significant association was found between cognitive
impairment and hearing impairment. The presence of
APOE-4 allele was associated with a 2.0-fold increased
risk of hearing impairment, compared with those without
the APOE-4 allele (Table 2). The odds ratio remained
similar after adjustment for cardiovascular disease, stroke,
and cognitive impairment was made.
4. Discussion
In the Leiden 85-plus Study, a population-based study in
85 year olds, the presence of the APOE-4 allele was
associated with age-related hearing loss over all frequen-
cies. We showed a dose–response relationship between
Fig. 2. Hearing loss, measured in the best ear, in relation to APOE ge-
notype.hearing loss and increasing presence of the APOE-4 allele.
Those with the APOE-4/4 genotype had the highest level
of hearing loss; those with the APOE-3/4 or 2/4 geno-
type had intermediate levels of hearing loss; and those
without the APOE-4 allele had the lowest levels of hearing
loss. These findings were independent of atherosclerosis
and cognitive function.
Our findings that the APOE genotype is associated with
age-related hearing loss has, to our knowledge, not been
described before and fit within the view that age-related
hearing loss cannot only be attributed to outer hair cell
dysfunction of the cochlea. Moreover, we argue that our
findings are important because the contribution of, for in-
stance, APOE (Fig. 1) to age-related hearing loss ranges
between 6- and 10-dB hearing loss, thus explaining for
10–15% of age-related hearing loss in the high-frequency
range (4000–8000 Hz) and 20–30% of age-related hearing
loss occurring in the lower-frequency range (250–2000 Hz).
The association between hearing loss and the
APOE-4 may well be found in the numerous actions of
APOE. First, APOE is unique among apolipoproteins, in
its special relevance to nervous tissue. It mobilizes and
redistributes lipids, playing an important role in the re-
innervation process of both the peripheral and central
nervous systems (Ignatius et al., 1986). Second,
APOE-4 is of particular interest concerning age-related
disorders because it strongly contributes to neurodegen-
erative disorders such as dementia (Corder et al., 1993)
and macular degeneration (Paternoster et al., 2010; Mc-
Kay et al., 2011), generalized atherosclerosis, and stroke
(Martínez-González and Sudlow, 2006; Biffi et al.,
2010). Finally, APOE has been shown to have antioxi-
dant and anti-inflammatory effects (Van Vliet et al.,
2009). Improvement of the reinnervation process, reduc-
Table 2
Hearing impairment and cardiovascular disease, cognitive impairment,
and presence of the APOE-4 allele







Odds ratio (95% CI) 1a 2.4 (1.5–3.8) 0.001
Cognitive impairmentb
Odds ratio (95% CI) 1a 1.5 (0.8–2.8) 0.2
APOE-4 allele
Odds ratio (95% CI) 1a 2.0 (1.1–3.9) 0.03
ultivariate modelc
APOE-4 allele
Odds ratio (95% CI) 1a 2.0 (1.0–4.0) 0.04
a Reference category.
b Presence of cognitive impairment is defined as a Mini-Mental State
Examination score lower than 24 points.
c Risk of hearing impairment in subjects with the APOE-4 allele, after
adjustments are made for cardiovascular disease, cognitive impairment,
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These protective effects are generally weakest for
APOE-4 and strongest for APOE-2. Therefore,
APOE-4 allele carriers may be at an increased risk of
hearing impairment.
4.1. Strengths and limitations
A unique feature of the current study is the population-
based sample of the very old, enabling us to answer the
question whether APOE contributes to hearing loss. People
aged 85 years are an ideal population to study possible
causes of age-related hearing loss. The largest increase in
prevalence of hearing loss occurs in participants aged 80
years and more (Gates and Mills, 2005; Cruickshanks et al.,
1998). We used the pure-tone audiometry in measuring
hearing loss, which is the most accepted method to deter-
mine age-related hearing loss in the general population and
population-based studies. We did not use speech audiome-
try because of the clinical features of age-related hearing
loss, which consist of threshold shifts and the decline of
speech understanding (Pichora-Fuller et al., 2006).
We found that our results were unaffected when adjusted
for possible confounders (atherosclerosis, stroke, and cog-
nitive impairment) associated with age-related disorders and
APOE genotype, which suggests that these confounders did
not significantly influence the effect of APOE on hearing
impairment. A limitation is the small number of homozy-
gote APOE-4/4 participants (n  6) in our study, that is,
which suggests that our study lacks power, when one limits
the analysis to homozygote APOE-4/4 only. However, in
our study we showed a significant gene–dose relationship
between hearing loss and increasing presence of the
APOE-4 allele, that is, those with the APOE-4/4 geno-
type had the highest level of hearing loss, those with the
APOE-3/4 or 2/4 genotype had intermediate levels of
hearing loss, and those without the APOE-4 allele had the
lowest levels of hearing loss. Moreover, despite the small
numbers of homozygote APOE-4/4 participants, a signif-
icant effect of APOE-4/4 on hearing loss and hearing
impairment was found when compared with participants
without the APOE-4 allele, suggesting the strength of the
effect of homozygote APOE-4 on age-related hearing loss.
Another possible limitation could be possible differences in
prevalence of APOE-4 genotype compared with younger
populations. The overall presence of APOE-4 genotype,
that is, APOE-4 carriers, in our study was 21.8%. Preva-
lence figures of APOE-4 carriers in one Dutch population
study and two international studies were roughly similar
compared with our study (Longitudinal Aging Study Am-
sterdam [Gerritsen et al., 2011], 25.4%, mean age 75 years,
n  911; Framingham Heart Study [Kardaun et al., 2000],
0.3%, mean age 76 years, n  840; and Honolulu Asia
ging study [van Himbergen et al., in press], 18.3%, meange  77 years, n  3459).. Conclusion
Our study shows an apparent dose–response relationship
etween APOE genotype, that is, presence of the APOE-4
llele and hearing loss over all frequencies at old age. These
ndings suggest that APOE contributes to age-related hear-
ng loss; however, independent confirmation of our novel
ndings in larger cohorts is necessary.
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